Effects of osteoblast-derived extracellular vesicles on aggressiveness, redox status and mitochondrial bioenergetics of MNNG/HOS osteosarcoma cells.
apoptosis
bioenergetics
cell communication
extracellular vesicles
mitochondria
osteosarcoma
redox status
tumour microenvironment
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
06
2022
accepted:
02
11
2022
entrez:
22
12
2022
pubmed:
23
12
2022
medline:
23
12
2022
Statut:
epublish
Résumé
Osteosarcoma is the most common primary bone malignancy. The crosstalk between osteosarcoma and the surrounding tumour microenvironment (TME) drives key events that lead to metastasization, one of the main obstacles for definitive cure of most malignancies. Extracellular vesicles (EVs), lipid bilayer nanoparticles used by cells for intercellular communication, are emerging as critical biological mediators that permit the interplay between neoplasms and the tumour microenvironment, modulating re-wiring of energy metabolism and redox homeostatic processes. We previously showed that EVs derived from the human osteosarcoma cells influence bone cells, including osteoblasts. We here investigated whether the opposite could also be true, studying how osteoblast-derived EVs (OB-EVs) could alter tumour phenotype, mitochondrial energy metabolism, redox status and oxidative damage in MNNG/HOS osteosarcoma cells.These were treated with EVs obtained from mouse primary osteoblasts, and the following endpoints were investigated: i) cell viability and proliferation; ii) apoptosis; iii) migration and invasive capacity; iv) stemness features; v) mitochondrial function and energy metabolism; vi) redox status, antioxidant capacity and oxidative molecular damage. OB-EVs decreased MNNG/HOS metabolic activity and viability, which however was not accompanied by impaired proliferation nor by increased apoptosis, with respect to control. In addition, OB-EV-treated cells exhibited a significant reduction of motility and
Identifiants
pubmed: 36544705
doi: 10.3389/fonc.2022.983254
pmc: PMC9762506
doi:
Types de publication
Journal Article
Langues
eng
Pagination
983254Informations de copyright
Copyright © 2022 Ponzetti, Ucci, Puri, Giacchi, Flati, Capece, Zazzeroni, Cappariello, Rucci and Falone.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Br J Cancer. 2019 Jan;120(1):45-53
pubmed: 30413828
Anal Biochem. 1990 Nov 1;190(2):360-5
pubmed: 2291479
Int J Mol Sci. 2021 Jun 02;22(11):
pubmed: 34199590
Mol Neurodegener. 2020 Mar 13;15(1):20
pubmed: 32169097
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Vet J. 2008 Jan;175(1):69-75
pubmed: 17851099
Oxid Med Cell Longev. 2018 Nov 8;2018:5076271
pubmed: 30533171
Int J Mol Sci. 2021 Oct 13;22(20):
pubmed: 34681692
J Neurochem. 2008 May;105(3):677-89
pubmed: 18194214
Clin Sci (Lond). 2014 Sep;127(6):367-73
pubmed: 24895057
Mol Cell. 2016 Mar 3;61(5):667-676
pubmed: 26942671
Nat Rev Mol Cell Biol. 2020 Jul;21(7):363-383
pubmed: 32231263
Free Radic Biol Med. 2014 Nov;76:25-33
pubmed: 25101517
Nat Rev Immunol. 2002 Aug;2(8):569-79
pubmed: 12154376
Oxid Med Cell Longev. 2016;2016:6235641
pubmed: 27418953
Sci Signal. 2013 Jul 23;6(285):ra61
pubmed: 23882120
Front Oncol. 2020 Mar 10;10:331
pubmed: 32211337
Nat Commun. 2021 May 14;12(1):2804
pubmed: 33990571
Cell Death Dis. 2017 Oct 12;8(10):e3113
pubmed: 29022891
Oxid Med Cell Longev. 2015;2015:750798
pubmed: 26273424
Blood. 2014 Oct 30;124(18):2834-46
pubmed: 25139351
J Cell Physiol. 2009 May;219(2):334-43
pubmed: 19115234
Nat Commun. 2022 Apr 4;13(1):1789
pubmed: 35379825
Oncol Lett. 2019 May;17(5):4213-4221
pubmed: 30944616
Eur J Histochem. 2022 Jun 22;66(3):
pubmed: 35730574
Nat Rev Clin Oncol. 2017 Jan;14(1):11-31
pubmed: 27141887
Cancer Res. 1987 Jun 15;47(12):3239-45
pubmed: 2438036
Oncol Rep. 2020 Aug;44(2):499-508
pubmed: 32627008
Stem Cell Reports. 2017 Feb 14;8(2):387-400
pubmed: 28162996
Cell Biol Int. 2018 May;42(5):580-588
pubmed: 29323455
Free Radic Biol Med. 2015 Oct;87:84-97
pubmed: 26117330
Cancers (Basel). 2022 Mar 25;14(7):
pubmed: 35406442
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
J Bone Oncol. 2015 Dec 12;5(1):5-14
pubmed: 26998421
Oxid Med Cell Longev. 2016;2016:3837623
pubmed: 28116035
Biochem Pharmacol. 2022 Apr;198:114983
pubmed: 35227643
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Indian J Orthop. 2014 May;48(3):238-46
pubmed: 24932027
Int J Radiat Biol. 2016 May;92(5):281-6
pubmed: 26940444
Biochem Med. 1983 Apr;29(2):143-8
pubmed: 6134525
Bone. 2021 Dec;153:116130
pubmed: 34329816
Chembiochem. 2020 Oct 1;21(19):2854-2860
pubmed: 32415808
Microrna. 2020;9(3):187-197
pubmed: 31849293
PLoS One. 2012;7(10):e48334
pubmed: 23110231
Curr Protoc Immunol. 2015 Nov 02;111:A3.B.1-A3.B.3
pubmed: 26529666
BMC Cancer. 2012 Apr 04;12:139
pubmed: 22475227
Cancer Sci. 2018 Dec;109(12):3686-3694
pubmed: 30312515
Curr Pharm Des. 2015;21(28):4088-94
pubmed: 26381269
Int J Biochem Cell Biol. 2012 Dec;44(12):2144-51
pubmed: 22981632
Tumour Biol. 2015 Mar;36(3):1329-38
pubmed: 25666750
Methods Mol Biol. 1998;108:107-10
pubmed: 9921520
SICOT J. 2018;4:12
pubmed: 29629690
Antioxidants (Basel). 2018 Jan 16;7(1):
pubmed: 29337889
Sci Rep. 2017 Sep 13;7(1):11470
pubmed: 28904402
Oxid Med Cell Longev. 2019 Nov 15;2019:4647807
pubmed: 31915507
J Cell Mol Med. 2021 Dec;25(23):11016-11030
pubmed: 34741385
Int J Biochem Cell Biol. 2008;40(12):2762-70
pubmed: 18585472
Methods Mol Biol. 2020;2109:225-229
pubmed: 31414347
J Inherit Metab Dis. 2015 Jul;38(4):681-702
pubmed: 25687155
J Bone Miner Res. 2020 Feb;35(2):396-412
pubmed: 31610048
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Front Cell Dev Biol. 2022 Mar 09;10:849962
pubmed: 35356277
Nat Med. 2012 Jun;18(6):883-91
pubmed: 22635005
J Neurosci Methods. 2009 Feb 15;177(1):122-30
pubmed: 18996411
Hypertens Res. 2016 May;39(5):342-8
pubmed: 26763852
Front Oncol. 2020 Feb 28;10:256
pubmed: 32185131
Am J Physiol Renal Physiol. 2022 Mar 1;322(3):F344-F359
pubmed: 35100813
Antioxidants (Basel). 2019 Sep 01;8(9):
pubmed: 31480513
Cell Death Differ. 2018 Jan;25(1):104-113
pubmed: 29149101
Methods Mol Biol. 2018;1709:107-127
pubmed: 29177655
Fitoterapia. 2022 Jul;160:105203
pubmed: 35489582
Annu Rev Cell Dev Biol. 2014;30:255-89
pubmed: 25288114
Int J Cancer. 2009 Jul 1;125(1):229-34
pubmed: 19330840
Rheumatol Ther. 2016 Dec;3(2):221-243
pubmed: 27761754
Nat Rev Cancer. 2017 May;17(5):302-317
pubmed: 28303905
Cells. 2022 Apr 04;11(7):
pubmed: 35406784
Biochem J. 2002 Mar 1;362(Pt 2):401-12
pubmed: 11853549
Nat Cell Biol. 2015 Jun;17(6):816-26
pubmed: 25985394